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Abst ract  Adjunct bright-light herapy has been sug- 
gested to augment antidepressant drug treatment in pa- 
tients with non-seasonal major depression. Side effects of 
the combined therapy have not been investigated thus far. 
Therefore, somatic complaints and side effects of com- 
bined therapy were evaluated in 28 patients with major 
depression (DSM-III-R) randomly assigned to either tri- 
mipramine or trimipramine and serially applied adjunct 
bright-light therapy. Response rates were comparable in 
both treatment groups and rates of newly emergent side 
ef fects  during treatment were generally low. The most 
prominent unfavourable side effects of adjunct bright-light 
therapy as compared with trimipramine monotherapy were 
aggravated sedation, persisting restlessness, emerging sleep 
disturbance and decreased appetite as well as the worsen- 
ing of vertigo. Discriminant analysis revealed that the com- 
bination of trimipramine with bright light results in a dif- 
ferent side effect profile compared with drug monotherapy. 
Key words  Bright-light therapy • Side effects •Major 
depression - Adjunct therapy 
Introduction 
Bright-light therapy (BLT) is considered an effective 
treatment inpatients uffering from seasonal affective dis- 
order (SAD) [26]. The mechanism of action is,  however, 
not yet completely understood. Preliminary data suggest 
actions on circadian rhythms including phase-shifting and 
amplitude-modulating properties [4, 11, 16]. Light is as- 
sumed to act on melatonin secretion and metabolism via 
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the retinal-hypothalamic-pineal pathway [28]; serotoner- 
gic effects of bright light have also  been proposed [19, 
20]. According to the phase-shift hypothesis, BLT admin- 
istered in the evening should delay the phase-advance of 
circadian rhythmicity which was proposed for patients 
with non-seasonal MDD [10, 16]. Durations of 1-2 h 
daily with full-spectrum bright light of 2500-5000 lux for 
1 week are regarded sufficient for treatment responses [8, 
27]. However, accepted guidelines for duration and dos- 
age of BLT in MDD patients are not established thus far. 
Besides its therapeutic effects in SAD patients bright 
light is also a non-pharmacological ndidate for adjunct 
treatment innonseasonal major depressive disorder (MDD) 
to augment the efficacy of antidepressant drugs [9, 14, 23] 
and partial sleep deprivation [17]. However, due to clini- 
cal evidence, the efficacy of adjunct BLT in MDD patients 
is equivocal thus far [24, 29, 31]. A major argument in 
favour of non-pharmacological adjunct reatments is their 
assumed safety, an issue which has to be evaluated empir- 
ically. Regarding BLT, few systematic reports are presently 
available [8, 12, 15, 18, 30]. The results indicate BLT to 
possibly catalyze switches from depression to (hypo-)ma- 
nia, and to cause several ess severe side effects such as 
headache, ye strain, and irritability, which should not be 
disregarded. 
Compared with other treatments, however, BLT rarely 
led to treatment discontinuation and was generally as- 
sumed to be well tolerated [21]. Nevertheless, the current 
state of research is incomplete and there are some restric- 
tions of interpretability of the available data: some studies 
lack a control group, one study used light visors [15] and 
may therefore be specific to that echnique, and the inves- 
tigated uration of BLT was limited to 1-2 weeks. The re- 
lationship between duration of treatment and occurrence 
rate of side effects is unclear. However, the emergence of 
side effects of BLT appeared to be independent of light in- 
tensity and treatment response [ 15]. To our knowledge, no 
previous tudy has focussed on the side effects of adjunct 
BLT in patients uffering from non-seasonal MDD. 
As pharmacotherapy is the standard treatment in MDD 
patients, the question should be raised as to whether ad- 
junct BLT changes the side effect profile of an antidepres- 
sant drug. Additionally, MDD patients often suffer from a 
variety of somatic complaints which could either posi- 
tively or negatively be influenced by treatment side ef- 
fects. Thus, depressive symptoms, side effects of antide- 
pressant drug therapy and of adjunct BLT might interact 
in MDD patients. The treatment of severely depressed 
MDD patients with either tr imipramine monotherapy or 
combined trimipramine and BLT yielded comparable re- 
sponse rates for both treatment modalities [7]. The present 
evaluation of this study compared side effects of 4 weeks 
adjunct BLT to a monotherapy with trimipramine. To in- 
vestigate the safety of adjunct BLT and the side effects of 
combined treatment the following issues were addressed 
in an exploratory approach: 
1. Emergence rates and change scores of side effects dur- 
ing the course of treatment 
2. Differences in side effect profiles between trimipra- 
mine monotherapy and combined treatment with BLT 
Methods 
Subjects and study design 
The total study comprised 42 patients with non-seasonal MDD ac- 
cording to DSM-III-R [1] randomly allocated to one of three treat- 
ment arms [trimipramine monotherapy (TRI), trimipramine and 
adjunct sleep deprivation, trimipramine and adjunct bright-light 
(TRI+BLT)] [7]. Any physical i lness was carefully ruled out. For 
the present evaluation only the groups TRI and TRI+BLT were 
considered (n = 14, each group). Table t shows a summary of rel- 
evant sociodemographic and psychometric parameters. All pa- 
tients were severely depressed, ratings of severity of depression 
[17-item Hamilton Depression Rating Scale (HDRS)] [6] were 
>18 at week 1 of treatment. All participants gave informed consent 
prior to the study; the protocol was approved by the local ethics 
council. 
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Protocol 
Both groups (TRI, TRI+BLT) received standard treatment with 
trimipramine; atthe start of the study (week 1) the previous med- 
ication (antidepressants, benzodiazepines, neuroleptics or combi- 
nations) was replaced by 100 and 150 mg trimipramine on days 1 
and 2, respectively. Pre-treatment was comparable between the 
treatment groups. From day 3 onwards all patients received 200 
mg trimipramine, administered as single dose at 7 p.m. for the rest 
of the 6-week study period. All patients were treated with trimi- 
pramine monotherapy during week 1; group TRI+BLT addition- 
ally received BLT during weeks 2-5 of treatment course (Fig. I). 
Light-therapy procedure 
Bright light ('full-spectrum', 5000 lux, 2 h, 5:30 to 7:30 p.m.) [2] 
was administered bymeans of a light 'wall' containing fluorescent 
lamps (2.5 m height, 5 m width) in a separate room; the patients 
were instructed tosit in front of the light wall and glance briefly at 
the light once or twice per minute while engaged in reading or 
desk work. The intensity of 5000 lux was achieved by controlling 
for the distance between the patient's eyes and the light wall (1.5 
m). The patients were continually supervised by trained staff. 
Dosage and frequency of treatments is shown in Fig. 1. 
Assessment of side effects 
For assessment of side effects a differentiated standard instrument 
[Fischer's Somatic Symptom/Undesired Effect Checklist (FSUCL)] 
[3] was used. The FSUCL comprises six different facets of side ef- 
fect items (central nervous ystem related, 5 items; gastrointestinal 
complaints, 6 items; vegetative, 5 items; neurological, 7 items; 
headache, 1 item; cardiovascular, 2 items) with a total of 26 items. 
Each item is scored on a 4-point scale, with 0 indicating absence 
and 3 indicating serious severity. Neurological side effects did not 
occur and were therefore xcluded from analyses. The rating scale 
was completed weekly at the same time (12.00 h) by a physician 
blind to treatment modality during a semi-structured interview. 
Data analyses 
The items of the FSUCL were analysed separately and combined 
(sum score). As base rates of side effects, FSUCL scores differing 
from 0 during week 1 (trimipramine therapy in both groups) were 
Table 1 Patient characteris- 
tics. TRI trimipramine 
monotherapy (200 mg/d); 
TRI+BLT trimipramine and ad- 
junct bright-light therapy; 
HDRS 17-item Hamilton De- 
pression Rating Scale 
Values are mean + SD 
~mComparisons with week 1
(paired t-test within each 
group; groups were compared 
with unpaired t-tests) 
at = 3.9, df= 13, p = 0.002 
bt=8.6, df= 13, p < 0.0005 
ct = 3.8, df= 13, p = 0.002 
at = 3.7, df= 13, p = 0.003 
TRI TRI+BLT Group differences 
N 14 14 - 
DSM-III-R diagnosis 
296.2 5 4 
296.3 7 8 
296.5 2 2 
Age (years) 50.6 _+ 8.5 55.1 + 10.6 n.s. 
Gender (female : male) 5 : 9 9 : 5 n.s. 
HDRS 
Week 1 26.0 + 6.4 22.7 + 5.2 n.s. 
Week 2 19.4 + 9.2 a 17.8 _+ 6.4 ~ n.s. 
Week 5 8.6 + 8.4 b 14.5 + 5.6 d t = 2.2, dr= 26, p = 0.04 
Duration of illness (years) 2.9 _+ 3.5 8.0 _+ 8.6 t = 2.1, df = 26, p = 0.06 
No. of admissions 1.7 + 0.9 3.6 _+ 4.9 n.s. 
No. of depressive episodes 2.9 _+ 2.t 4.1 _+ 5.0 n.s. 
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Fig. 1 Study protocol. TR[ trimipramine; BLT bright-light therapy; 
bright light (5:30 to 7:30); FSUCL Fischer's Somatic Symp- 
tom/Undesired Effect Checklist; HDRS 17-item Hamilton Depres- 
sion Rating Scale 
recorded. Accordingly, the rates of newly emerging symptoms un- 
der ongoing treatment ('emergence rates', i.e. scorings differing 
from 0 if baseline value was 0) were assessed in week 2 and dur- 
ing the course of week 2 to week 5 (scores differing from 0 for at 
least 1 week during weeks 2-5). Group differences in symptom 
frequencies were computed by Z 2 tests. The change in symptoms 
was expressed as raw score differences between week 2 and 1 
(A2-1, acute effects), week 5 and t (A5-1, 4-week effects), and 
week 6 and 5 (A6-5, withdrawal), respectively. The FSUCL vari- 
ables were analysed for group differences between TRI and 
TRI+BLT. To detect relationships between antidepressant response 
and side effects, group differences in FSUCL change scores be- 
tween responders (improvement of at least 50% in HDRS score in 
week 5 compared with baseline) and nonresponders were ana- 
lysed. For analyses of group differences unpaired t-tests were used. 
Discriminant analyses (stepwise procedure using Wilks X) were 
performed for A2-1 and A5-1 in order to explore the separation of 
the treatment groups on the basis of side effect change score pro- 
files. Significantly discriminating variables were compared jointly 
by MANOVA based on Wilks X statistics. Due to the exploratory 
nature of the study and to reduce type-II errors, the level of signif- 
icance was set at ~ = 0.10. 
Results 
Total scorings of  undesired effects and somatic complaints 
(FSUCL total score) showed significant changes during 
the course of treatment in group TRI (week 1:10.6 _+ 5.6, 
week 5 :5 .0  + 5.3; paired t-test, t = 5.8, df = 13, p < 
0.0005), but not in TRI+BLT (week 1:10.7 +4.0, week 5: 
8.3 + 5.9; t = 1.6, df= 13, p > 0.10). However, no signifi- 
cant difference between treatment groups at weeks 1 and 
5 was obtained. Furthermore, no baseline differences in 
single FSUCL item scores could be detected (data not 
shown). The frequency of patients with emerging specific 
side effects during acute (week 2) and 4-week treatment 
(weeks 2-5)  is summarized in Table 2 for TRI  and 
TRI+BLT (emergence rates). The basel ine rates (week 1, 
tr imipramine treatment; number of patients with scores > 
0) are also shown for comparison. Evidently, most of  the 
symptoms assessed by FSUCL occurred frequently in 
both treatment groups in week 1. No substantial differ- 
ences in the rate of newly emergent side effects, neither 
during week 2 nor during weeks 2-5,  could be found. 
Changes in FSUCL item scores after 1 (week 2) and 4 
weeks (week 5) of l ight treatment and after discontinua- 
tion of BLT (week 6) are provided in Table 3 for both 
groups. Despite comparable numbers of  patients with side 
effects in both groups (TRI and TRI+BLT), significant 
group differences in change scores could be stated indi- 
Table 2 Baseline rates and 
emergence of side effects 
(FSUCL) in treatment groups. 
FSUCL Fischer's omatic 
symptom/undesired effect 
checklist; TRI trimipramine 
monotherapy (200 rag/d); 
TRI+BLT trimipramine and 
adjunct bright-light therapy 
NOTE: Values are numbers 
(percentages in parentheses) of 
patients (n = 14, each group) 
with side ffects present in 
week 1 (base rates) or with 
newly emergent side effects in 
week 2 or during weeks 2-5 
(emergence rates) 
Group difference: X2 = 4.5, 
df= 1,p < 0.05 
Base rates Emergence rates Emergence rates 
Week 1 Week 2 Weeks 2-5 
TRI TRI+BLT TRI TRI+BLT TRI TRI+BLT 
(n= 14) (n=14) (n=14) (n=14) (n=14) (n=14) 
Sedation 10 (71) 11 (79) 
Disturbed sleep 12 (86) 13 (93) 
Restlessness 11 (79) 11 (79) 
Agitation 6 (43) 7 (50) 
Disorientation 0 (0) 1 (7) 
Miction complaints 2 (14) 2 (I4) 
Dry mouth 9 (64) 9 (64) 
Salivation 0 (0) 1 (7) 
Sweating 6 (43) 8 (57) 
Impaired accommodation 5 (36) 6 (43) 
Decreased appetite 8 (57) 4 (29) 
Increased appetite 1 (7) 7 (50) ~ 
Stomach pain 2 (14) 5 (36) 
Nausea 0 (0) 0 (0) 
Constipation 4 (29) 3 (21) 
Diarrhoea 1 (7) 0 (7) 
Headache 2 (14) 5 (36) 
Vertigo 5 (36) 6 (43) 
Hypotension 2 (14) 3 (21) 
2 (I4) 0 (0) 2 (14) 0 (0) 
0 (0) 0 (0) 0 (0) 0 (0) 
0 (0) 0 (0) 0 (0) 0 (0) 
1 (7) 1 (7) 1 (7) 1 (7) 
0 (0) 0 (0) 1 (7) 0 (0) 
2 (14) 1 (7) 2 (14) 1 (0) 
0 (0) 1 (7) t (7) 1 (7) 
0 (0) 0 (0) 0 (0) 0 (0) 
0 (0) 2 (14) 1 (7) 4 (29) 
2 (14) 0 (0) 2 (14) 1 (7) 
1 (7) 1 (7) 1 (7) 3 (21) 
3 (21) 0 (0) 6 (43) 1 (7) 
0 (0) 0 (0) 2 (14) 0 (0) 
0 (0) 0 (0) 0 (0) 1 (7) 
1 (7) 1 (7) 3 (21) 2 (14) 
0 (0) 1 (7) 0 (0) 1 (7) 
0 (0) 0 (0) 0 (0) 2 (14) 
0 (0) t (7) 0 (0) 2 (14) 
0 (0) 1 (7) 0 (0) 2 (14) 
Table 3 Side effect (FSUCL) and symptom (HDRS) changes in treatment groups 
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Acute effects Effects after 4 weeks Discontinuation effects 
A week 2-1 A week 5-1 zX week 6-5 
TRI TRI+BLT TRI TRI+BLT TRI TRI+BLT 
(n = 14) (n = 14) (n = 14) (n = 14) (n = 14) (n = 14) 
Sedation -0,1 -+ 0.6 0.5 + 1.0 b -0.9 + 0.8 -0.5 _+ 0.9 0.0 _+ 0.9 0.1 + 1.0 
Disturbed sleep ¢,d -1,1 _+ 0.8 -0.5 + 1.0 -1.2 + 0.9 -0.5 + 0.8 b -0.5 _+ 0.7 -0.3 -+ 0.6 
Restlessness c,d -0.7 .+ 0.8 -0.2 -+_ 0.6 ~ -1.2 +_ 0.8 -0.5 _+ 0.9 ~ 0.1 +_ 0.5 0.1 +_ 0.5 
Agitation -0.2 +_ 0.6 -0.5 -+ 0.8 -0.5 .+ 0.7 -0.6 +_ 0.7 -0.1 .+ 0.3 0.0 _+ 0.0 
Disorientation 0.0 + 0.0 0.0 + 0.0 0.1 + 0.3 0.0 + 0.0 -0.1 _+ 0.3 0.0 .+ 0.0 
Miction complaints 0.0 + 0.6 0.0 + 0.7 0.1 + 0.5 0.0 + 0.7 -0.1 _+ 0.4 0.0 + 0.0 
Dry mouth 0 .5+1.1  0 .5+1.1  -0 .2+1.0  0.1 + 1.0 0.0_+0.9 0.0 + 0.8 
Salivation 0 .0+0.0  -0.1 +0.3 0.0_+0.0 -0.1 _+0.3 0.0_+0.0 0 .0+0.0  
Sweating ° -0.2 _+ 0.8 ~3.2 + 0.9 -0.5 +_ 0.8 -0.3 _+ 0.6 0.2 + 0.7 -0.1 _+ 0.9 
Impaired accommodation 0.4 _+ 0.7 0.0 _+ 0.8 0.0 + 0.8 0.2 -+ 0.9 0.1 _+ 0.4 0.1 .+ 0.3 
Decreased appetite ~,d -0.5 + 1.2 -0.2 + 0.8 -0.9 _+ 0.9 -0.1 _+ 1.0 a 0.1 _+ 0.7 0.1 _+ 0.3 
Increased appetite ° 0.4 +_ 0.8 0.2 + 0.8 0.3 + 0.9 0.0 + 1.4 -0.1 .+ 0.4 -0.1 + 0.8 
Stomach pain 0.0 .+ 0.4 -0.1 .+ 0.6 -0.2 .+ 0.4 -0.3 _+ 0.5 0.1 + 0.5 0.1 -+ 0.4 
Nausea 0.0 + 0.0 0.0 + 0.0 0.0 + 0.0 0.0 _+ 0.0 0.0 _+ 0.0 0.1 + 0.4 
Constipation d 0 .2+0.4  0.1 +0.7 -0.1 + 1.0 0.1 +0.6 -0.1 _+0.6 0,1 _+0.3 
Diarrhoea -0.1 + 0.3 0.1 .+ 0.3 -0.1 +- 0.3 0.0 +_ 0.0 0.0 .+ 0.0 0.1 +_ 0.3 
Headache 0.1 +0.5 -0.3 _+0.5 a -0.1 +0.3 -0.3.+ 1,0 -0 . i  .+0.3 0.2_+0.9 
Vertigo -0.1 _+ 0.5 0.1 _+ 0.5 -0.5 _+ 0.8 0.1 _+ 0.9 b 0.3 _+ 0.6 -0.1 _+ 0.7 b 
Hypotension c,d -0.1 _+0.3 0.0_+0.4 -0.1 _+0.3 0.2_+0.7 0.0_+ 0.0 -0.1 _+0.6 
HDRS sum score °,d 45.6 _+ 6.3 -4.9 + 4.9 -17.4 + 7.6 -8.2 + 8.3 a ~).3 +_ 4.8 -0.9 .+ 5.3 
NOTE: Values are mean + SD of symptom changes (A) 
a, b Differences between treatment groups (TRI vs TRI+BLT, un- 
paired t-test): ~t > 1.7, df= 26, p < 0.05; bt > 1.3, df= 26, p < 0.10 
~,~ Differences between responders and nonresponders (HDRS, un- 
paired t-test): ¢ Aweek 2-1, t > 1.3, df= 26,p < 0.10; d Aweek 5-1; 
Table 4 Results of discriminant analyses 
t > 1.3, df= 26, p < 0.10; HDRS responders (improvement > 50% 
in week 5) showed more favourable changes in all significant dif- 
ferences 
A2-1 
TRI TRI+BLT 
zX5-1 
p TRI TRI+BLT p 
Sedation 
Restlessness 
Decreased appetite 
Constipation 
Impaired accommodation 
Sleep disturbance 
Headache 
Vertigo 
MANOVA 
- -  + 
- -  + 
- -  + 
+ 
+ 
F = 4.3, df= 5;20, p = 0.008 
0.02 
0.05 
0.006 
0.01 
0.005 
- + 0.005 
- + 0.01 
+ - 0.05 
- + 0.02 
F = 5.1, df= 4;21, p = 0.005 
NOTE: Values are signs and p-values of standardized discriminant 
function coefficients; + increase or weak decrease; - decrease or 
weak increase of symptoms; the signs are indicative for the re- 
spective treatment group; zX2-1 score differences between weeks 2 
and 1; eX5-1 score differences between weeks 5 and 1. Only sig- 
car ing d i f ferences  in the perce ived  in tens i ty  (scores 0 -3 )  
of  s ide effects.  Wi th  respect  to acute ef fects  (week  2) in- 
c reased  sedat ion  (p < 0. I0)  and  improved headaches  (p < 
0.05) cou ld  be  observed  in the group  BLT+TRI  as com-  
pared  w i th  TRI ,  whereas  rest lessness  howed a reduced 
improvement  (p < 0.05) in pat ients  on  BLT+TRI  treat- 
nificantly (p _< 0.05) discriminating variables are reported. Dis- 
criminant analyses were carried out on 10 of 19 symptoms due to 
omission of variables without considerable between-group vari- 
ance 
ment .  A f te r  4 weeks  of  ad junct  t reatment ,  s leep distur-  
bances  (p < 0.10),  rest lessness  (p < 0.05),  and  decreased  
appet i te  (p < 0.05) showed less improvement  in the group  
BLT-TR I  when compared  w i th  pat ients  t reated wi th  TRI .  
As  shown in Tab le  3, on average  group  TR I  benef i t ted  
more  than pat ients  t reated wi th  TR I+BLT .  However ,  
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Amelioration Worsening < I 
J 
Sedation - 
Restlessness 
Decreased appetite- 
Constipation - 
Impaired accommodation- 
week 2 -1  
r 
I 
\ 
I i 
Restlessness ]- * ~ . > ~  
Sleep disturbance ~ (,) 
Headache 1 
Vertigo ]A week 511  ~ I 
-1.5 1 -0.5 0 0.5 
Change of FSUCL score 
Fig.2 Change profiles of discriminative symptoms. Values are 
mean and SEM; filled circle trimipramine; open circle trimipra- 
mine and bright-light therapy; zk2-1 difference (week 2-1); A5-1 
difference (week 5-1); (*  p < 0.10; *p < 0.05 (unpaired t-tests) 
HDRS response rates were 11 of 14 (78%) patients for 
TRI and 6 of 14 (43%) patients for TRI+BLT, respec- 
tively. This difference was statistically not significant 
(X 2 = 2.4, df= 1, p > 0.10). Therefore, side effect change 
scores were descriptively compared between responders 
(n = 17) and non-responders (n = 11) of the merged 
groups to elucidate the dependence of side effect changes 
on treatment response. Table 3 indicates the FSUCL 
change scores with significant differences between HDRS 
responders and non-responders and shows that changes in 
sedation, headache and hypertension were not dependent 
on treatment response. Table 4 yields results from dis- 
criminant analyses for changes between week 1 and week 
2 (A2-1) or week 5 (A5-1), respectively. Items without 
substantial between group variance were omitted; only 
clearly discriminating items (p < 0.05) are presented. 
Both discriminant functions were statistically signifi- 
cant (2x2-1: Wilks X = 0.48, df= 5,p = 0.008; A5-1: Wilks 
)~ = 0.51, df= 4, p = 0.005). On the basis of the discrimi- 
nant functions allocation to treatment groups was possible 
with 85% accuracy (zX2-1 and A5-1); sensitivity (group 
BLT) reached 92 and 69%; specificity reached 77 and 
100%, for A2-1 and A5-1, respectively. 
The discrimination of both treatment groups according 
to changes in side effects yielded different profiles of side 
effect changes for acute and 4-week effects (Fig. 2). 
> Discussion 
The present study shows that the combination of an anti- 
depressant drug with bright light results in a different side 
effect profile compared with drug monotherapy. However, 
adjunct bright light did not evoke additional severe symp- 
toms in major depressive patients and is therefore consid- 
ered to be safe. 
Taking into account baseline scores of depressive 
symptoms and side effects due to standard treatment with 
a tricyclic antidepressant drug, the evaluation of addi- 
tional bright-light effects is apparently confounded. Dry 
mouth, sweating, disturbance of accommodation, vertigo 
and sedation were predominating side effects during the 
baseline treatment with trimipramine. These findings are 
in line with other studies and might be primarily attribut- 
able to anticholinergic mechanisms [5]. Furthermore, sleep 
disturbance, restlessness, agitation and decreased appetite 
occurred in a substantial proportion of patients as part of 
their depressive syndrome. The acute effects of intensive 
BLT applied daily for 1 week did not lead to a substantial 
further emergence of specific side effects. An augmenta- 
tion of antidepressant efficacy, however, also did not oc- 
cur, although from studies in SAD patients a gradual im- 
provement during 1 week of BLT could have been ex- 
pected [26]. 
The lack of further improvement could be due to sev- 
eral factors, e.g. different biological or sociodemographic 
conditions of the two groups despite random assignment 
[7]. Although similar numbers of patients with or without 
specific side effects were found in both treatment groups, 
moderate but reliable differences in the perceived severity 
of side effects emerged. More complicated is the fact that 
side effects of bright light seem to be covered by delayed 
improvement of particular symptoms of depression such 
as restlessness, sleep disturbance and decreased appetite. 
These symptoms showed faster and more pronounced im- 
provement in treatment responders. Our results therefore 
suggest a partial dependence of side effects on the treat- 
ment outcome notwithstanding results from a previous 
study [15]. Discriminant analyses [20] revealed patterns 
of symptom changes eparating the tr atment modalities. 
Accentuated sedation, ameliorated constipation and ac- 
commodation problems during acute adjunct BLT (week 
2) showed no relationship to treatment outcome. This 
finding points to specific properties of BLT. Despite the 
significant discriminating power of these variables, only 
the group difference in sedation reached significance indi- 
cating distinct but mild effects. Increased sedation and de- 
layed improvement of subjective sleep disturbance during 
additional BET was unexpected: according to the hypoth- 
esized phase-delaying propea~des, evening bright light 
should improve morning sleep and reduce sleepiness the 
following day [13]. However, the limited empirical evi- 
dence from studies using evening light revealed also the 
occurrence of disturbed sleep in 5 of 8 SAD patients [12]. 
After 4 weeks of adjunct therapy, reduced complaints 
about headache but aggravated vertigo occurred indepen- 
dently of treatment course. As regards the latter, improve- 
ment after discontinuation of BLT was found; the amelio- 
ration of headache under BLT partially conflicts with pre- 
vious reports [8, 15, 18]. In one study [15], however, re- 
mission of headache occurred in 28% of patients as op- 
posed to an emergence of the symptom in 19% of patients. 
A major difference between this and previous studies 
is that in our clinical study all patients tarted with a tri- 
cyclic anti-depressant treatment. Thus, base rates of symp- 
toms due to side effects were much higher than expected 
for untreated patients and improvement of symptoms was 
more probable due to ceiling and regression effects. How- 
ever, as depressive illness comprises a variety of symp- 
toms and sub-syndromes, including somatic complaints, 
and vegetative symptoms, expected side effects of antide- 
pressants could interact with response in different ways: 
antidepressants or combinations could result in 'positive' 
side effects (e.g. activation in retarded patients, sleepiness 
in sleepless patients), thus becoming desired effects. 
On the other hand, the emergence of side effects which 
are components of illness symptomatology may cause 
worsening of the illness course. That bright light may 
cause dramatic changes in affective state was demon- 
strated in studies on SAD patients, as some patients de- 
veloped hypomanic or manic states after exposure to BLT 
[8, 12, 18]. From the present study there is no evidence 
for such adverse effects of adjunct bright light in MDD 
patients. However, the group treated with adjunct BLT 
comprised only 2 patients with bipolar disorder (DSM-III- 
R 296.5). Additionally, delayed recovery from depression 
due to other factors, (baseline severity, biological vari- 
ables, sociodemographic parameters) may be associated 
with delayed improvement in somatic complaints [7]. 
These influences could be confounded with the side ef- 
fects of either treatment and it seems impossible to disen- 
tangle such relationships in our naturalistic study. Never- 
theless, the relatively rare and mild side effects attribut- 
able to adjunct BLT resulted in a characteristic alteration 
in the side effect profile of the tricyclic antidepressant 
trimipramine with both positive or ameliorating and wors- 
ening or aggravating aspects. Interpretation of the present 
results should, however, take into account hat a relatively 
high intensity of BLT was used. Whereas augmenting 
light intensity has been proposed to provide greater bene- 
fit [25], results of a previous study [t5] indicated no rela- 
tionship between side effects and intensity of light used. 
As a further limitation, the present study used no addi- 
tional placebo or sham treatment condition. Although in 
the case of BLT an accurate double-blind condition cannot 
be achieved, no differences between bright and dim light 
conditions (50 vs 2500 Iux) could be found with respect to 
emerging side effects [30]. However, as no previous tudy 
has evaluated side effects of combined pharmacotherapy 
and BLT, the question as to which side effects of adjunct 
BLT were definitely attributable to bright light remains 
unclear. 
Since the mechanism of action for BLT in depression 
still needs to be unraveled, it can only be speculated about 
underlying mechanisms leading to the observed side ef- 
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fect changes: the pattern of specific acute side effect 
changes of combined TRI+BLT therapy comprising in- 
creased restlessness, decreased appetite as well as amelio- 
rated constipation and accommodation problems is tenta- 
tively in line with a serotonergic mechanism of BLT as 
proposed by Rao et al. [20]. These authors found substan- 
tially elevated blood serotonin profiles after phototherapy 
in healthy subjects and in MDD patients, however, with- 
out reporting side effects or symptom changes. 
This could also explain why BLT led to a specific 
change of pre-existing side effects of TRI therapy and 
suggests the evaluation of side effect profiles as an addi- 
tional clinical tool for research in BLT. The results are in 
need of replication with larger sample sizes and using a 
placebo condition (dim light). In keeping with the litera- 
ture, adjunct bright light can - with respect o the restric- 
tions of the present data - be regarded as safe. However, 
prior to including adjunct light therapy routinely in treat- 
ment programs of non-seasonal MDD, the efficacy has to 
be verified, and further studies investigating potential side 
effects of combined treatments are indispensable. 
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